イブチリドヘミフマル酸塩

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

イブチリドヘミフマル酸塩 価格

イブチリドヘミフマル酸塩 化学特性,用途語,生産方法

• 外観

  白色～ほとんど白色粉末～結晶

• 効能

  抗不整脈薬, カリウムチャネル遮断薬

• 説明

  Covert was launched in the US and UK for treatment of atrial fibrillation and flutter and can be synthesized in three steps from N-phenyl rnethanesulfonamide. While ibutilide has an asymmetric center, it has been determined that the racemate is equipotent with either enantiomer. The antiarrhythmic action is derived from the compounds ability to prolong the action potential duration and lengthen the refractory period of myocardial tissue. Class Ⅲ antiarrhythrnic agents accomplish this by blocking outward potassium channels, however, ibutilide elicits the same effect by activation of slow inward sodium channels. Recent evidence indicates that it also is a potent blocker of the rapidly acting delayed rectifier potassium current (l_kr)and may block the ATP-inhibited potassium channel.

• 化学的特性

  White to Off-White Solid

• 使用

  A methanesulfonanilide antiarrhythmic agent; prologns myocardial action potential duration, predominantly by activation of slow inward sodium current. Antiarrhythmic (class III).

• 臨床応用

  Ibutilide (Corvert) is a structural analog of sotalol and produces cardiac electrophysiological effects similar to those of the antiarrhythmic agents in class III.
  Ibutilide is approved for the chemical cardioversion of recent-onset atrial fibrillation and atrial flutter. Ibutilide appears to be more effective in terminating atrial flutter than atrial fibrillation. It can also lower the defibrillation threshold for atrial fibrillation resistant to chemical cardioversion.

• 副作用

  The major adverse effect associated with the use of ibutilide is the risk of torsades de pointes due to QT prolongation. Other reported adverse cardiovascular events (all 2%) include hypotension and hypertension, bradycardia and tachycardia, and varying degrees of A-V block. The incidence of noncardiac adverse events with the exception of nausea does not differ from that of placebo.

• 薬物相互作用

  Ibutilide has significant drug interactions.

• 予防処置

  Contraindications to the use of ibutilide include baseline prolongation of the QT interval, use of other QTprolonging drugs, history of torsades de pointes, hypersensitivity to ibutilide, uncorrected hypokalemia or hypomagnesemia, and pregnancy or breast-feeding.

イブチリドヘミフマル酸塩 上流と下流の製品情報

イブチリドヘミフマル酸塩 生産企業

Global(242)Suppliers

イブチリドヘミフマル酸塩 スペクトルデータ(¹HNMR)

122647-32-9, イブチリドヘミフマル酸塩 キーワード